Navigation Links
Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
Date:2/25/2010

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients. Researchers from the Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Thomas Jefferson University Medical School, Arkansas Epilepsy Program, Schwarz Biosciences and Johns Hopkins University Hospital conducted this study which is available early online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

Epilepsy is one of the most common neurologic disorders, affecting up to 2% of the worldwide population according to the Centers for Disease Control and Prevention (CDC). More than half of the total epilepsy population experience POS, or focal seizures, which occur in one part of the brain. While several anti-epileptic drugs have entered the market in the past decade, approximately 30% of patients with epilepsy experience recurrent seizures and undesirable side effects from their medication. There remains a significant unmet need for well-tolerated medications able to provide adequate seizure control. Lacosamide is emerging as a promising candidate to reduce seizure frequency and severity with few adverse effects.

The efficacy and safety of adjunctive lacosamide for POS was established in three multicenter, randomized, double-blind, placebo-controlled trials. Results of the first trial indicated that study participants taking 400 and 600 mg/day of lacosamide experienced significantly larger reductions in seizure frequency and significantly greater responder rates compared with placebo. Two additional phase III trials were conducted in parallel to confirm these results.

Steve Chung, M.D., and colleagues report the results of the second phase III trial, which was conducted in an expanded patient population of 405 men and women, aged 16-70 in the U.S. The primary objective of the trial was to evaluate the efficacy of lacosamide 400 and 600 mg/day as adjunctive treatment for POS; the secondary objective was to further assess the safety, potential dose-response relationships, and steady-state plasma concentrations of lacosamide and concomitant antiepileptic drugs (AEDs). This trial randomized patients 1:2:1 to placebo, lacosamide 400 mg, or lacosamide 600 mg/day. After an 8-week baseline period, patients began treatment with placebo or lacosamide 100 mg/day, were force-titrated weekly (100 mg/day increments) to the target dose, and entered a 12-week maintenance period. Study participants had at least a 2-year history of POS despite treatment with at least two AEDs (concurrently or sequentially) and were experiencing at least four partial-onset seizures per 28 days, with no seizure-free period longer than 21 days during the 8 weeks prior to baseline and during the 8-week baseline period.

Adjunctive treatment with lacosamide 400 and 600 mg/day was found to be effective in reducing the frequency of POS (with or without secondary generalization) in patients with uncontrolled seizures while taking one to three concomitant AEDs. Of the 338 patients completing titration, 274 (81.1%) achieved their target dose of trial medication without the need for dose reduction prior to entry into maintenance.

"The efficacy results observed in this trial are notable given the epilepsy treatment history and the frequency of the seizures experienced by enrolled patients," said Dr. Michael Sperling one of the study authors. "Despite this difficult-to-treat study population, treatment with lacosamide 400 and 600 mg/day resulted in significant reductions from baseline in seizures, as well as significantly higher responder rates and a higher rate of seizure freedom compared with placeboresults that are comparable to established and second-generation AEDs."


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V)
2. New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings
3. Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug
4. UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
5. UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
6. iCardiac's Highly Automated QT(sm) Technology Cross-Validated Against Results from Five Leading ECG Core Laboratories
7. Heart failure risk model validated
8. BioMosaics Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer
9. Life Line Screening Data on Peripheral Arterial Disease Validated
10. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
11. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area ... about women’s hair loss. Although hair transplant procedures can be seen as more of ... genetics can be two reasons a woman may see her hair thinning. , “We ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... satisfaction in their profession as their value increases in the healthcare workforce, according ... resources such as job boards, career fairs, and candidate leads to healthcare employers ...
(Date:3/27/2017)... ... 2017 , ... New patients who have sleep apnea in Aurora, ... without a referral. Sleep apnea is often left untreated because patients are not familiar ... chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea in ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to experience the benefits ... now have them placed by Dr. Manju Kejriwal, with or without a referral. Dr. ... increase the accuracy of each dental implant placement. The i-CAT CBCT system captures the ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... transitioned to the OSEHRA popHealth Community in 2014. It is the ... and the Developer Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology: